PDI2
Based on 1 Customer Validation
PDI2 (PSMA-DOTA-PEI2) is a prostate-specific membrane antigen (PSMA) ligand that acts as a tumor retention agent, renal uptake reducer, imaging agent and antitumor agent, applicable in SPECT diagnostic imaging and radiotheranostics. PDI2 specifically binds to PSMA on prostate cancer cells, enters cells via clathrin-dependent endocytosis, and exhibits higher tumor retention rate and lower renal uptake level. PDI2 is applicable in research related to prostate cancer and castration-resistant metastatic prostate cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.00%
- CAS 番号: 3110124-60-9
- 分子式: C59H90N12O19
- 分子量:1271.41
-
保管条件:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
Radionuclide-Drug Conjugates (RDCs) アイソフォーム固有の製品をすべて表示
More
生物活性
[111In]In-PDI2 (0.195-50 nM; incubated on ice for 2 h) binds specifically to PSMA on LNCaP cells, with a Kd value of 22.8 nM[1].
[111In]In-PDI2 (37 kBq; incubated on ice for 2 h, incubated at 37°C for 0-4 h) shows an internalization rate of 38.9% in LNCaP cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
PDI2 (5-10 kBq; i.v.; single dose) effectively inhibits the growth of PSMA-positive LNCaP prostate cancer xenografts with no obvious toxicity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nu/nu (male, 5-6 weeks old)[1]
-
Dosage:111 kBq
-
Administration:i.v.; single dose
-
Result:Measured 20.74% ID/g tumor accumulation at 4-h postinjection; measured 25.47% ID/g tumor accumulation at 24-h postinjection; measured 13.54% ID/g tumor accumulation at 96-h postinjection; measured 52.31% ID/g renal uptake at 4-h postinjection; measured 4.85% ID/g renal uptake at 24-h postinjection; achieved 7.3 tumor-to-kidney radioactivity ratio.
化学情報
-
CAS 番号 3110124-60-9
-
性状 Solid
-
分子量 1271.41
-
分子式 C59H90N12O19
-
Color White to off-white
-
別名
PSMA-DOTA-PEI2
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
溶剤 & 溶解度
DMSO : 1 mg/mL (0.79 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
純度とドキュメンテーション
-
データシート (270 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
取扱説明書 (2659 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
PDI2 関連分類
HY-P11591 関連分類
Powered by Bioz
- PDI2
- 3110124-60-9
- PSMA-DOTA-PEI2
- PDI 2
- PDI-2
- Radionuclide-Drug Conjugates (RDCs)
- PSMA
- PSMA-positive LNCaP prostate cancer xenografts
- SPECT/CT
- prostate-specific membrane antigen
- metastatic castration-resistant prostate cancer
- prostate cancer
- prostate cancer cells
- targeted radionuclide therapy
- LNCaP cells
- clathrin-dependent endocytosis
- Inhibitor
- inhibitor
- inhibit